Sign Out
There is currently no known antidote to reverse the effects of Ticagrelor (BRILINTA), and Ticagrelor (BRILINTA) is not dialysable (see Pharmacology: Pharmacokinetics under Actions). Treatment of overdose should follow local standard medical practice. The expected effect of excessive Ticagrelor (BRILINTA) dosing is prolonged duration of bleeding risk associated with platelet inhibition. If bleeding occurs, appropriate supportive measures should be taken.
Ticagrelor is well tolerated in single doses up to 900 mg. GI toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse effects which may occur with overdose include dyspnoea and ventricular pauses.
In the event of overdose, observe for these potential adverse effects and consider ECG monitoring.
